Clinical trials: Squamous Cell Carcinoma (SCC), active
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Squamous Cell Carcinoma
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell…
- Trial name
- HCHTOG2603 (NCT07629817)
- Testing
- Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy, Radiation with Concurrent Chemotherapy, Radical Esophagectomy
- Where
- China
- Volunteers
- 1,044 people
- Sponsor
- Henan Cancer Hospital
HPV, Oropharyngeal Squamous Cell Carcinoma
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
- Trial name
- NCT04965792
- Testing
- Screening
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Hnscc, Head and Neck
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this Phase 1 clinical trial is to evaluate the safety and feasibility of nivolumab-IRDye800CW (nivo800) as a molecular imaging agent in adults with biopsy-confirmed or presumed head and neck squamous cell carcinoma…
- Conditions
- Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma
- Trial name
- NCT07460765
- Testing
- Nivo800, Nivolumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma
Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
This phase I trial tests the safety and side effects radiotherapy in combination with atezolizumab in treating patients with cutaneous squamous cell cancer that has spread to nearby tissue or lymph nodes (locally advanced) and…
- Conditions
- Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
- Trial name
- NCT05085496
- Testing
- Atezolizumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
This study is exploring the use of Panitumumab in Head and Neck Cancer. Panitumumab is an approved drug named Vectibix and is used as an anti-cancer agent in other cancers such as colorectal cancer.
- Conditions
- HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
- Trial name
- NCT06819228
- Testing
- Panitumumab IRDye 800
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Oropharyngeal Cancer, Human Papilloma Virus
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic…
- Conditions
- Oropharyngeal Cancer, Human Papilloma Virus, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05582590
- Testing
- Fludarabine, Cyclophosphamide, NEXI-003 T cells
- Volunteers
- 36 people
- Sponsor
- NexImmune Inc.
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC
A prospective collection of 35 cases was conducted at Zhujiang Hospital of Southern Medical University. Patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous…
- Trial name
- NCT07133958
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhujiang Hospital
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients.
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC
- Trial name
- NCT06736379
- Testing
- VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- VLP Therapeutics
SCC - Squamous Cell Carcinoma, Upper Aero-digestive Tract (UADT) Neoplasm
Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.
Squamous cell carcinomas of the upper aero-digestive tract (SCC-UADT) represent the seventh cause of cancer and affect approximately 600,000 patients per year worldwide.
- Trial name
- CIRADOR (NCT06479070)
- Testing
- Blood samples
- Where
- 7 sites in France, Switzerland
- Volunteers
- 188 people
- Sponsor
- Institut de Cancérologie de Lorraine
HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma
Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and[18F]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during…
- Conditions
- HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
- Trial name
- NCT07741643
- Testing
- Panitumumab-IRDye800, [18F]NOTA-ABY-030
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Squamous Cell Cancer (SCC), Recurrent Laryngeal Nerve Palsy
CT and Endoscopic Biopsy Image-Based Deep Learning for Predicting Left Recurrent Laryngeal Nerve Lymph Node Metastasis in Esophageal Cancer
The goal of this observational study is to develop a predictive model for left recurrent laryngeal nerve (RLN) lymph node metastasis using deep learning algorithms.
- Conditions
- Esophageal Squamous Cell Cancer (SCC), Recurrent Laryngeal Nerve Palsy, Deep Learning, Postoperative Complication
- Trial name
- NCT07074535
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Squamous Cell Carcinoma, RP1
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
This is a Phase 1b, single-center, open-label study, evaluating efficacy and safety of RP1 for the treatment of resectable cutaneous Squamous Cell Carcinoma in up to 12 evaluable patients.
- Trial name
- NCT05858229
- Testing
- RP1
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sherrif Ibrahim
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
HNSCC, SCC - Squamous Cell Carcinoma
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical trial is to learn whether intratumoral (injected directly into the tumor) fluorescently labeled nivolumab (nivo800) is safe for adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled…
- Conditions
- HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer
- Trial name
- NCT07741565
- Testing
- Nivolumab-IRDye800
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
The goal of this clinical trial is to evaluate whether formulated methylene blue can safely and effectively treat advanced or inoperable Squamous Cell Carcinoma (SCC), a common type of skin cancer.
- Conditions
- SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin, Inoperable Disease
- Trial name
- NCT07311057
- Testing
- Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Daryoush Hamidi Alamdari, PhD
Keratinocyte Carcinoma, Basal Cell Carcinomas
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas.
- Conditions
- Keratinocyte Carcinoma, Basal Cell Carcinomas, Squamous Cell Carcinoma, Skin Cancer
- Trial name
- NCT07010692
- Testing
- Tirbanibulin ointment 1%, non-ablative fractional laser
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bruce Robinson, MD
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
- Trial name
- DUET-1 (NCT05120271)
- Testing
- CAR-GPC3 T Cells
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Sotio Biotech Inc.
Cutaneous Squamous Cell Carcinoma
Ex Vivo Cutaneous SCC
This is a prospective study including patients ( ≥ 18 years) referred for surgical treatment of primary cutaneous squamous cell carcinoma at the Department of Plastic Surgery, Rigshospitalet.
- Trial name
- NCT07402616
- Testing
- ex vivo 3D ultrasonography
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Oropharyngeal Squamous Cell Carcinoma (SCC)
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Background: Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against…
- Trial name
- NCT05996523
- Testing
- PRGN-2009, Pembrolizumab, EKG
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)